We are experiencing some temporary issues. The market data on this page are currently delayed. Please bear with us as we address this and restore your personalized lists.
|Bid||5.05 x 100|
|Ask||5.11 x 600|
|Day's Range||5.20 - 5.43|
|52 Week Range||3.23 - 10.54|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||11.92|
Aurinia Pharmaceuticals Inc. , a clinical stage biopharmaceutical company focused on the global immunology market, today announced that it has launched ALL INTM, an educational program for people living with lupus nephritis .
High growth companies such as Firan Technology Group and Aurinia Pharmaceuticals has a positive future outlook in terms of their returns, profitability and cash flows. The prospects of these companiesRead More...
Aurinia Pharmaceuticals Inc. , a clinical stage biopharmaceutical company focused on the global immunology market, today announced the appointment of Joseph P.
Aurinia Pharmaceuticals Inc., today announced that its Chief Executive Officer, Richard M. Glickman and Celia Economides, Vice President, Corporate and Public Affairs, will participate in a Fireside Chat at the Leerink Partners 7th Annual Global Healthcare Conference on February 14th at 2:30pm ET.
The downtrend in shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) may end soon — not from the renewed interest in biotech stocks but because of Aurina’s upcoming revenue potential. Aurina has a potential blockbuster drug, called Voclosporin, that is in the clinical stages. AUPH’s priorities during both its second and third quarter were the Aurora Phase III trial.
NEW YORK, NY / ACCESSWIRE / January 5, 2018 / On Thursday, all three major indexes rose for the third consecutive day, with the Dow Jones crossing the 25,000 plateau for the first time ever. The Dow Jones ...
Shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) fell nearly 5% in after-hours trading Thursday after it notified the SEC and shareholders that it would be able to sell up to $250 million in newly issued common stock as needed over a specified amount of time. This new "shelf registration," as it's called, replaced the previous registration that spanned the prior 25 months. If all shares under the new shelf registration are sold, it would result in significant dilution -- 60%.
Aurinia Pharmaceuticals Inc. today announced that in order to replace its prior expired base shelf prospectus and corresponding shelf registration statement it has filed a preliminary short form base shelf prospectus with the securities commissions in each of the provinces of Ontario, Alberta and British Columbia in Canada, and a corresponding shelf registration statement on Form F-10 with the U.S....
|Initiated||RBC Capital : to Outperform||2/8/2018|
|Initiated||Seaport Global : to Buy||10/6/2017|
|Downgrade||Canaccord Genuity : Buy to Speculative Buy||9/13/2017|
|Initiated||Cantor Fitzgerald : to Overweight||4/10/2017|
|Initiated||Mackie Research : to Speculative Buy||11/1/2016|
|Initiated||H.C. Wainwright : to Buy||6/30/2016|
Full Time Employees : 20
Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, engages in the development of a therapeutic drug to treat autoimmune diseases in Canada and internationally. The company is developing Voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis. It has partnership agreements with Paladin Labs Inc. and 3SBio, Inc. The company was formerly known as Isotechnika Pharma Inc. and changed its name to Aurinia Pharmaceuticals Inc. in October 2013. Aurinia Pharmaceuticals Inc. was founded in 1993 and is headquartered in Victoria, Canada.